참고문헌
- Ministry of Health and Welfare. Annual report of the central cancer registry in Korea. Seoul: Ministry of Health and Welfare 2001
- Hunter CP. Epidemiology, stage at diagnosis, and tumor biologyof breast carcinoma in multiracial and multiethnic populations. Cancer 2000;88:1193-1202 https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5+<1193::AID-CNCR3>3.0.CO;2-D
- Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer 2000;88:114-123 https://doi.org/10.1002/(SICI)1097-0142(20000101)88:1<114::AID-CNCR16>3.0.CO;2-J
- Chen VW, Correa P. Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarker Prev 1994;3:127-135
- Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994;86:705-712 https://doi.org/10.1093/jnci/86.9.705
- Stanford JL, Greenberg RS. Breast cancer incidence in young women by estrogen receptor status and race. Am J Public Health 1989;79:71-73 https://doi.org/10.2105/AJPH.79.1.71
- Ownby HE, Frederick J, Russo J, et al. Racial differences in breast cancer patients. J Natl Cancer Inst 1985;75:55-60
- Valanis B, Wirman J, Hertzberg VS. Social and biological factors in relation to survival among black vs. white women with breast cancer. Breast Cancer Res Treat 1987;9:135-143 https://doi.org/10.1007/BF01807366
- Shiao YH, Chen VW, Lehmann HP, Wu XC, Correa P. Patterns of DNA ploidy and S-Phase fraction associated with breast cancer survival in blacks and whites. Clin Cancer Res 1997;3:587-592
- Krieger N, avn den, Eeden SK, et al. Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: a study of white, black, and Asian women in San Francisco bay area. Ethn Dis 1997;7:137-149
- Choi DH, Lee MH, Allen EB, Carter D, Haffty BG. Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients. J Clin Oncol 2004;22:1638-1645 https://doi.org/10.1200/JCO.2004.04.179
- Choi DH, Shin DB, Lee MH, et al. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003;98:1587-1595 https://doi.org/10.1002/cncr.11703
- Choi DH, Lee MH, Ahn YH, et al. Characteristics of HER-2/neu oncogene in Korean Women with early-onset breast cancer by immunohistochemistry and fluorescence in situ hybridization. J Korean Breast Cancer Soc 2003;6:255-62 https://doi.org/10.4048/jkbcs.2003.6.4.255
- Singer-Ranger G, Mokbel K. The role of cyclooxygenase- 2 (COX-2) in breast cancer, and implications of COX-2 inhibition. European J Surg Cancer 2002:28;729-737
- Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent Ductal Carcinoma In Situ. Cancer Research 2002:62;1676-1681
- Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002:62;632-635
- Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 Is overexpressed in HER-2/neu positive breasr cancer. J Biol Chem 2002:277;18649-18657
- Costa C, Soares R, Reis-Filho JS, et al. Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002:55;429-434
- Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor2 (HER-2)/neu-induced breast cancer. Cancer Research 2002:62;5405-5407
- Spizzo G, Gas G, Wolf D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. British J Cancer 2003:88; 674-578
- Soslow RA, Dannenberg AJ, Rush D, et al. Cyclooxygenase- 2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000;89:2637-2645 https://doi.org/10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B
- Parret ML, Harris RL, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997;10:503-508
- Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival inpatients with breast carcinoma. Cancer 2003;97:2978-2987 https://doi.org/10.1002/cncr.11437
- Nam EM, Im SA, Kim DY, et al. Increased expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/neu and other clinicopathologic prognostic factors. The 28th Annual meeting of the Korean Cancer Association 2002 abstract#23
- Ahn JH, Kim SB, Ahn SH, et al. Clinical value of cyclooxygenase expression in human breast carcinoma. Cancer Res Treat 2004;36:192-198 https://doi.org/10.4143/crt.2004.36.3.192
- Song H, Koo TY, Park JH, et al. Inhibition of cyclooxygenase- 2 expression by Genistein in breast cancer cell-line. J Korean Breast cancer Soc 2003;6:277-282 https://doi.org/10.4048/jkbcs.2003.6.4.277
- Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase- 2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2000;60:1326- 1331
- Pyo H, Shin YK, Kim HS, Seong J, Suh CO, Kim GE. The enhancement of radiosensitivity by celecoxib, selective cyclooxygenase-2 inhibitor, on human cancer cells expressing differential levels of cyclooxyganase-2. J Korean Soc Ther Radiol Oncol 2003;21;216-221
- Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase- 2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:16-20 https://doi.org/10.1016/S0360-3016(02)03821-X
- Kim JB, Wu HG, Park SW, Kim CJ, Park CI. Expression of cyclooxygenase (COX)-2 as a prognostic factor in nasopharyngeal cancer. Cancer Res Treat 2004;36:187-191 https://doi.org/10.4143/crt.2004.36.3.187
- O'Connor JK, Avent J, Lee RJ, Fischbach J, Gaffney DK. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:1034-1040 https://doi.org/10.1016/j.ijrobp.2003.08.032
- Benoit V, Relic B, Leval XX, Chariot A, Merville MP, Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase- 2 and prostaglandin E2. Oncogene 2004;23:1631-1635 https://doi.org/10.1038/sj.onc.1207295
- Simeone AM, Li YJ, Broemeling LD, Johnson MM, Tuna M, Tari AM. Cyclooxygenase-2 is essential for HER2/ neu to suppress N-(4-Hydroyphenyl) retinamide apoptotic effects in breast cancer cells. Cancer Res 2004;64:1224-1228 https://doi.org/10.1158/0008-5472.CAN-03-2188
- Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase- 2 inhibitor, celecoxib, prevents the development of mammary tumors in HER-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003;12:1486-491
- Dang CT, Dannenberg AJ, Subbaramaiah K, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatment. Clin Cancer Res 2004;10:4062-4067 https://doi.org/10.1158/1078-0432.CCR-03-0463